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Abstract The importance of proper mutational analysis of
BRCA1/2 in individuals at risk for hereditary breast and ovar-
ian cancer syndrome is widely accepted. Standard genetic
screening includes targeted analysis of recurrent, population-
specific mutations. The purpose of the study was to establish
the frequency of germline BRCA1/2 mutations in a group of
134 unrelated patients with primary ovarian cancer. Next
generation sequencing analysis revealed a presence of 20
(14.9 %) mutations, where 65 % (n=13) were recurrent
BRCA1 alterations included in the standard diagnostic panel
in northern Poland. However, the remaining seven BRCA1/2
mutations (35 %) would be missed by the standard approach
and were detected in unique patients. A substantial proportion
(n=5/12; 41 %) of mutation-positive individuals with
complete family history reported no incidence of breast or
ovarian cancer in their relatives. This observation, together
with the raising perspectives for personalized therapy
targeting BRCA1/2 signaling pathways indicates the necessity
of comprehensive genetic screening in all ovarian cancer
patients. However, due to the limited sensitivity of the stan-
dard genetic screening presented in this study (65 %) an
application of next generation sequencing in molecular diag-
nostics of BRCA1/2 genes should be considered.
Keywords BRCA1 .BRCA2 . Mutations . Next generation
sequencing . Ovarian cancer . PARP inhibitors
Introduction
BRCA1 and BRCA2 germline mutations are associated with
high penetrance for both breast and ovarian cancer (Miki et al.
1994; Wooster et al. 1995). The overall prevalence of BRCA1/
2 alterations in general population varies considerably among
different ethnic groups, with respect to specific founder mu-
tations. In 2000, three founder alleles of BRCA1 (c.5266dup,
c.181T>G, c.4034delA) were reported in Polish families with
a strong aggregation of breast or ovarian cancers and subse-
quently incorporated into the standard genetic screening panel
(Gorski et al. 2000). Further investigations were expanded in a
large population of unselected female breast cancer patients
(Brozek et al. 2011; Gaj et al. 2012; Lubinski et al. 2006;
Szwiec et al. 2014) as well as in consecutive ovarian cancer
series (Brozek et al. 2008; Majdak et al. 2005; Menkiszak
et al. 2003). A relatively high germline mutation frequency at
the level of 13.5 % for BRCA1 and 13.9 % for BRCA1/2
among cases with unselective primary ovarian carcinoma
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has been reported in studies by Menkiszak et al. (2003) and
Brozek et al. (2008), respectively. Albeit both studies con-
firmed the strong founder effect for BRCA1 5266dup and
c.181T>G alterations, the latter reported other recurrent
BRCA1/2 mutations in the group of Polish patients with
ovarian cancer.
In line with the recommendations of the American Society
of Clinical Oncology testing for recurrent BRCA1mutations is
required in each case of ovarian cancer in the Polish popula-
tion (1996). According to the reports of the latest clinical trials
patients with BRCA mutations and recurrent serous ovarian
carcinoma may benefit from specific therapies targeting
BRCA signaling pathways (Audeh et al. 2010; Fong et al.
2009, 2010; Ledermann et al. 2012, 2014). For the purpose
of the most effective treatment as well as genetic counseling
and prophylactic strategies for patients and their families,
mutational analysis of BRCA1 and BRCA2 needs to be highly
sensitive and cost-efficient.
The aim of this study was to establish the frequency of
germline BRCA1/2 mutations in consecutive ovarian cancer
series from northern Poland. Additionally, it was of our inter-
est to investigate whether an application of next generation
sequencing can significantly improve BRCA1/2 mutation de-
tection rate and subsequently effectiveness of further prophy-
lactic and treatment strategies.
Materials and methods
Study material
The study comprises 134 unselected ovarian cancer patients
who were referred to the University Hospital in Gdansk and
the Red Cross Hospital in Gdynia between 2012 and 2013.
Within the studied group 77.6 % (n=104/134) of patients
were diagnosed with serous ovarian cancer, average age at
diagnosis was 60.8 (24–87) years. Informed consent was
obtained from all of the patients and the study was approved
by the medical review board ofMedical University of Gdansk.
DNA extraction
Genomic DNAwas extracted from the whole blood using red-
blood-cells lysis buffer followed by the standard phenol-
chloroform procedure as described elsewhere.
Mutational analysis
BRCA1 and BRCA2 mutation screening was performed using
the BRCA MASTR assay v1.2 (Multiplicom, Niel, Belgium)
followed byMiSeq targeted re-sequencing at minimum of 99x
coverage (Illumina Inc.). The cut-off of 20%was applied. The
analysis was performed with Illumina Variant Studio Software
(Illumina Inc.) and Geneious Software (Biomatters Ltd).
Presence of the BRCA1/2mutations detected by NGS analysis
was confirmed by PCR followed by bi-directional Sanger
sequencing (ABI PRISM 3130, Life Technologies, Inc.).
Results
In the group of 134 patients with unselected primary ovarian
cancer, pathogenic BRCA1 or BRCA2 mutations were found
in 20 individuals (14.9 %). In addition, two variants of un-
known significance were detected (BRCA1: c.301+7G>A;
BRCA2: c.9486_9488del). Among the BRCA1/2 positive
cases, 16 carried BRCA1 and four BRCA2 mutation, which
accounts for 80 and 20 %, respectively. Thirteen alterations
(n=13/20; 65%) were recurrent BRCA1mutations included in
the standard genetic screening panel used in northern Poland,
as previously reported (Ratajska et al. 2008). The remaining
seven mutations (n=7/20; 35 %), three located in BRCA1 and
four in BRCA2 are not included in the standard targeted
mutation analysis, which overall gives seven out of the 20
mutation positive cases (35 %). All these mutations were
detected in unique patients. Detailed clinical, histopathologi-
cal and molecular data of BRCA1/2 positive patients are
presented in Table 1.
Out of the 20 BRCA1/2 positive patients, 17 were diag-
nosed with ovarian serous adenocarcinoma (85 %), whereas
the other three with adenocarcinoma endometroides (15 %).
Overall, the frequency ofBRCA1/2mutations was 40% (n=9/
22) in the group diagnosed before or at age of 50 and approx-
imately 10 % among patients older than 50 years (n=11/112).
The mean age of cancer diagnosis was 52 (24–82) years in the
group of mutation carriers and 62.3 (27–87) years in patients
with BRCA1/2 wild-type. Finally, detailed family history was
available only in 60 % (n=12/20) of BRCA1/2 positive pa-
tients, of whom in five individuals it was negative for breast/
ovarian cancer in first and second degree relatives (41 %).
Discussion
The percentage of BRCA1/2 mutations in unselected ovarian
cancer patients identified in the current study is comparable to
that previously reported (14.9 vs 13.5 and 13.9 %) (Brozek
et al. 2008; Menkiszak et al. 2003). The worldwide prevalence
of BRCA1/2 mutations in consecutive ovarian cancer series is
estimated at 5 to 15 % and varies markedly depending on the
population’s ethnic background (Berchuck et al. 1998;
Malander et al. 2004; Risch et al. 2001). Effective and cost-
efficient targeted mutation analysis is widely performed in
patients with familial history of breast and ovarian cancer,
including population-specific founder mutations. Since the
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implementation of genetic screening panel covering the three
founder mutations in 2000, there have been subsequent re-
ports on the prevalence of other recurrent BRCA1/2mutations
in Poland (Brozek et al. 2008; Gaj et al. 2012; Gorski et al.
2004; Perkowska et al. 2003; Ratajska et al. 2008; Szwiec
et al. 2014). Based on these reports, the standard testing panel
has been expanded to five BRCA1 alterations in northern
Poland (Ratajska et al. 2008). Furthermore, more recently,
Szwiec et al. (2014) proposed to test six BRCA1 mutations
in a group of women diagnosed with breast cancer at the age
of 50 or below.
It is widely accepted that the differences in frequency and
spectrum of BRCA1/2 mutations may result from an applica-
tion of different molecular techniques or ethnic diversity even
within the same country (Brozek et al. 2011; van Der Looij
et al. 2000).
To validate usefulness of targeted assays in screening for
BRCA1/2mutations, we performed a next generation sequenc-
ing in the group of 134 patients with unselected ovarian
cancer. Based on the results we conclude that the sensitivity
of genetic screening covering the three founder BRCA1 mu-
tations (c.5266dup, c.181T>G, c.4034delA) is established at
50 % (only ten out of 20 mutations). Expanded panel, com-
prising two additional recurrent mutations in BRCA1
(c.3700_3704del and c.68_69delAG) increases detection rate
to 65 %.
In the present study fairly high frequency of previously
selected mutations was confirmed. c.5266dup was the most
common BRCA1 alteration detected in the studied group (n=
8/13; ∼62 %). The second most common BRCA1 mutation
was a frame shift deletion c.3700_3704del (n=3/13; 23 %).
The c.3700_3704del mutation is frequently detected in the
Caucasian populations and has been reported as one of the
three most prevalent alterations in north-eastern and south-
central Poland, along with the c.5266dup and c.181T>G
(Brozek et al. 2008, 2011; Gaj et al. 2012; Ratajska et al.
2008; Szwiec et al. 2014). Furthermore, a relatively low
frequency of the other two founder mutations, c.4034delA
and c.68_69delAG in our region denotes heterogenity of
BRCA1 alterations in Polish patients with ovarian cancer.
The remaining seven mutations detected in BRCA1 and
BRCA2 genes were identified only in unique patients.
However, all detected genetic variants have been previously
reported in the Breast Cancer Information Core (BIC) data-
base (Szabo et al. 2000).
Interestingly, within this study a relatively high proportion
of deleterious BRCA2 mutations (20 %) was observed. For
instance, a c.2808_2811del deletion identified in an 82-year
old patient is a recurrent mutation, frequently detected in non-
Ashkenazi breast/ovarian cancer patients and described to
have multiple origins (Infante et al. 2013). The other BRCA2
genetic variants detected in the current study, although less
frequent, were also previously reported (Szabo et al. 2000).
A substantial percentage of BRCA1/2 positive patients
diagnosed after the age of 60 (n=8/20) is consistent with the
previous reports, indicating that the incidence of ovarian can-
cer in older age does not exclude BRCA germline mutation,
especially as far as the BRCA2 gene is concerned (Brozek
et al. 2012; Risch et al. 2001). Limited significance of age at
diagnosis as well as patient’s family history justifies genetic
screening for the founder BRCA1/2 mutations in all ovarian
cancer patients. However, according to the current study, as
many as 35 % of mutation positive individuals can be missed
in the routine screening. This proportion can be even higher
after taking into account possible large rearrangements in
BRCA genes that were not examined in the present study.
Though, as previously reported (Ratajska et al. 2008;
Rudnicka et al. 2013) these BRCA1/2mutations are relatively
rare (3.7 and 4.8 % of all BRCA1 alterations, respectively) in
the Polish population, we cannot entirely exclude their occur-
rence. Moreover, a deletion comprising exon 17 has been
detected in two unrelated Polish high-risk breast and ovarian
cancer families (Rudnicka et al. 2013).
The importance of mutation detection, apart from genetic
counselling and prophylactic management arises in the
considerance of recent clinical trials, with the implementation
of poly (ADP-ribose) polymerase 1 (PARP1) inhibitors.
PARP1 is a member of chromatin-associated polymerases
involved in posttranslational ADP-ribosylation and DNA
strand breaks repair (El-Khamisy et al. 2003; Lindahl et al.
1995). It has been reported that tumor cells with BRCA1/2
mutation, since their deficiency in homologous recombina-
tion, are markedly sensitized to the PARP inhibition, resulting
in chromosomal instability and consequent apoptosis (Bryant
et al. 2005; Farmer et al. 2005). According to the results of
phases 1 and 2 trials with PARP1 inhibitor Olaparib, BRCA
mutation positive patients with platinum-sensitive relapsed
serous ovarian cancer respond preferentially to PARP inhibi-
tion, with a significant reduction in risk of disease progression
in comparison to patients with wild-type BRCA (Audeh et al.
2010; Fong et al. 2009, 2010; Ledermann et al. 2012, 2014).
These observations raise promising perspectives for personal-
ized therapy in BRCA carriers and further emphasizes the
necessity for proper mutational analysis of BRCA1/2 in a
group of ovarian cancer patients.
Conclusions
In conclusion, we propose routine genetic screening for at
least five recurrent BRCA1 mutations (c.5266dup,
c.181T>G, c.3700_3704del, c.68_69delAG, c.4034delA) in
all ovarian cancer patients in the Polish population. In addi-
tion, in the negative cases for above-mentioned alterations
analysis of the entire BRCA1/2 genes with an application of
new generation sequencing should be performed.
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Unfortunately, given the potential costs of such expanded
diagnostics it will probably need to be limited to the selected
group of patients with specific clinical and histopathological
characterization. To establish recommendations for the entire
BRCA1/2 genes mutational analysis further studies in larger
ovarian cancer series with detailed family history are required.
Moreover, based on the results we confirm that next genera-
tion sequencing is a sensitive, reliable tool which can be
applied in molecular diagnostics of BRCA1/2 genes in a group
of selected patients.
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